EBS - Emergent BioSolutions Inc.
63.33 0.00 (0.00%)
After hours: 5:31PM EST
| Previous Close | 63.72 |
| Open | 66.10 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 62.04 - 67.45 |
| 52 Week Range | 46.49 - 73.89 |
| Volume | 716,334 |
| Avg. Volume | 392,606 |
| Market Cap | 3.226B |
| Beta (3Y Monthly) | 1.56 |
| PE Ratio (TTM) | 32.33 |
| EPS (TTM) | 1.96 |
| Earnings Date | Feb 20, 2019 - Feb 25, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 70.43 |
- GuruFocus.com•29 minutes ago
Emergent BioSolutions Inc (EBS) Files 10-K for the Fiscal Year Ended on December 31, 2018
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. Emergent BioSolutions Inc had annual average EBITDA growth of 11.30% over the past ten years. Warning! GuruFocus has detected 5 Warning Signs with EBS.
- Thomson Reuters StreetEvents•7 hours ago
Edited Transcript of EBS earnings conference call or presentation 21-Feb-19 10:00pm GMT
Q4 2018 Emergent BioSolutions Inc Earnings Call
- Zacks•11 hours ago
Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
Emergent (EBS) rides high on both earnings and a revenue beat in Q4.
Motley Fool•yesterdayEmergent Biosolutions Inc (EBS) Q4 2018 Earnings Conference Call Transcript
EBS earnings call for the period ending December 31, 2018.
- Associated Press•yesterday
Emergent Biosolutions: 4Q Earnings Snapshot
GAITHERSBURG, Md. (AP) _ Emergent Biosolutions Inc. (EBS) on Thursday reported a fourth-quarter loss of $3.4 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 7 cents. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 61 cents per share.
- GlobeNewswire•yesterday
Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
GAITHERSBURG, Md., Feb. 21, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS.
- GlobeNewswire•8 days ago
Factors of Influence in 2019, Key Indicators and Opportunity within CVS Health, Solaris Oilfield Infrastructure, SK Telecom Co., Energizer, Emergent Biosolutions, and Quad Graphics — New Research Emphasizes Economic Growth
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•8 days ago
Who Has Been Selling Emergent BioSolutions Inc. (NYSE:EBS) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! It is not uncommon to see companiesRead More...
- Zacks•8 days ago
Earnings Preview: Emergent Biosolutions (EBS) Q4 Earnings Expected to Decline
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•11 days ago
Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
Emergent BioSolutions Inc. (EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its chairman and CEO from 2014 until 2018, when Adapt was acquired by Emergent. “The appointment of Seamus to Emergent’s Board comes at a pivotal time in the company’s history, when successive acquisitions have resulted in rapid growth and expansion,” said Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions.
- Markit•15 days ago
See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.
Emergent Biosolutions Inc NYSE:EBSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for EBS with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EBS totaled $1.37 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- GlobeNewswire•16 days ago
Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
GAITHERSBURG, Md., Feb. 07, 2019 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the.
- GlobeNewswire•last month
Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
Emergent BioSolutions Inc. (EBS) today announced the appointment of Robert G. Kramer, Sr. to the company’s Board of Directors. Effective April 1, 2019, Mr. Kramer will assume the role of president and CEO and will serve on the Emergent Board, succeeding Daniel J. Abdun-Nabi and filling the vacancy created by Mr. Abdun-Nabi’s retirement. Fuad El-Hibri, executive chairman of the board of Emergent BioSolutions, stated, “Bob embodies Emergent’s past and future.
- American City Business Journals•last month
An extended shutdown could bode poorly for local biotechs
Delays at the Food and Drug Administration could require companies to invest more money than they’d planned for already expensive trials.
- American City Business Journals•last month
MoCo economic development officials plan satellite office in Boston
Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.
- Zacks•last month
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
- American City Business Journals•2 months ago
Emergent BioSolutions CEO to step down
Daniel Abdun-Nabi will retire as CEO of Emergent BioSolutions Inc. (NYSE: EBS) after leading the Gaithersburg biotech through a pivotal seven-year period. Bob Kramer, the company’s current president and chief operating officer, will succeed Abdun-Nabi as president and CEO, effective April 1. Beginning April 1, he’ll serve as a consultant to the company, to provide guidance on strategic plan development, mergers and acquisitions, other transactions and regulatory matters, and to help with the executive transition, according to Securities and Exchange Commission filings.
- Zacks•2 months ago
Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
- GlobeNewswire•2 months ago
Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast
Full year 2018 preliminary performance in line with recently revised guidanceFull year 2019 forecast reflects continued growth of organic business and anticipated positive.
- Simply Wall St.•2 months ago
Our Take On Emergent BioSolutions Inc.’s (NYSE:EBS) CEO Salary
In 2012 Dan Abdun-Nabi was appointed CEO of Emergent BioSolutions Inc. (NYSE:EBS). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- GlobeNewswire•2 months ago
Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
Emergent BioSolutions Inc. (EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as president and CEO, effective April 1, 2019. Mr. Abdun-Nabi has also indicated that he plans to step down as a member of the Emergent board of directors, and Emergent expects the board of directors to appoint Mr. Kramer to fill the board vacancy created by Mr. Abdun-Nabi’s retirement.
- Zacks•2 months ago
Emergent (EBS) Files Application for Emergency Use of NuThrax
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
- GlobeNewswire•2 months ago
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
NuThrax, also known as AV7909, is being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure, in conjunction with the recommended course of antimicrobial therapy. This submission is anticipated to undergo review by FDA through the first half of 2019.
